Modeling and Simulation for Individualized Therapy of Amisulpride in Chinese Patients with Schizophrenia: Focus on Interindividual Variability, Therapeutic Reference Range and the Laboratory Alert Level
Shanqing Huang,Lu Li,Zhanzhang Wang,Tao Xiao,Xiaolin Li,Shujing Liu,Ming Zhang,Haoyang Lu,Yuguan Wen,Dewei Shang
DOI: https://doi.org/10.2147/DDDT.S327506
2021-09-14
Abstract:Shanqing Huang, 1, &ast Lu Li, 1, 2, &ast Zhanzhang Wang, 1, 2 Tao Xiao, 1 Xiaolin Li, 1 Shujing Liu, 1 Ming Zhang, 1, 2 Haoyang Lu, 1, 2 Yuguan Wen, 1, 2 Dewei Shang 1, 2 1 Department of Pharmacy, The Affiliated Brain Hospital of Guangzhou Medical University, Guangzhou, 510370, People's Republic of China; 2 Guangdong Engineering Technology Research Center for Translational Medicine of Mental Disorders, Guangzhou, 510370, People's Republic of China &astThese authors contributed equally to this work Correspondence: Dewei Shang; Yuguan Wen Department of Pharmacy, The Affiliated Brain Hospital of Guangzhou Medical University, 36 Mingxin Road, Guangzhou, 510370, People's Republic of China Tel +86-020-81268389 Fax +86-020-81891391 Email ; Purpose: To explain the high inter-individual variability (IIV) and the frequency of exceeding the therapeutic reference range and the laboratory alert level of amisulpride, a population pharmacokinetic (PPK) model in Chinese patients with schizophrenia was built based on therapeutic drug monitoring (TDM) data to guide individualized therapy. Patients and Methods: Plasma concentration data (330 measurements from 121 patients) were analyzed using a nonlinear mixed-effects modeling (NONMEM) approach with first-order conditional estimation with interaction (FOCE I). The concentrations of amisulpride were detected by HPLC-MS/MS. Age, weight, sex, combination medication history and renal function status were evaluated as main covariates. The model was internally validated using goodness-of-fit, bootstrap and normalized prediction distribution error (NPDE). Recommended dosage regimens for patients with key covariates were estimated on the basis of Monte Carlo simulations and the established model. Results: A one-compartment model with first-order absorption and elimination was found to adequately characterize amisulpride concentration in Chinese patients with schizophrenia. The population estimates of the apparent volume of distribution (V/F) and apparent clearance (CL/F) were 12.7 L and 1.12 L/h, respectively. Age significantly affected the clearance of amisulpride and the final model was as follows: CL/F=1.04×(AGE/32) − 0.624 (L/h). To avoid exceeding the laboratory alert level (640 ng/mL), the model-based simulation results showed that the recommended dose of amisulpride was no more than 600 mg/d for patients aged 60 years, 800 mg/d for those aged 40 years and 1200 mg/d for those aged 20 years, respectively. Conclusion: Dosage optimization of amisulpride can be carried out according to age to reduce the risk of adverse reactions. The model can be used as a suitable tool for designing individualized therapy for Chinese patients with schizophrenia. Keywords: amisulpride, population pharmacokinetics, therapeutic drug monitoring, modeling and simulation, individualized therapy Amisulpride, a substituted benzamide derivative, is a second-generation antipsychotic and a highly selective antagonist, which binds to dopamine D 2 /D 3 receptors. 1 Given its efficacy and tolerance, amisulpride has been suggested as a first-line treatment option in the management of schizophrenia. 2 However, high inter-individual variability (IIV) of amisulpride pharmacokinetics has been observed in patients, and overdosing may lead to serious adverse reaction. 3 Therapeutic drug monitoring (TDM) is the use of whole-blood plasma or serum drug (or metabolite) concentration measurements to assess adherence, guide dosage, and the highest possible probability of response and a minimized risk of adverse drug reactions/toxicity. The Arbeitsgemeinschaft für Neuropsychopharmacology und Pharmakopsychiatrie (AGNP) consensus guidelines considered TDM for amisulpride to be strongly recommended (level 1). The therapeutic reference range for amisulpride is 100–320 ng/mL, with a laboratory alert level of 640 ng/mL. 4,5 The apparent distribution volume, protein binding rate and absolute bioavailability of amisulpride were 5.8 L/kg, 16% and 48%, respectively. After repeated administration, amisulpride did not accumulate in vivo and the pharmacokinetic parameters did not change with dosage. The elimination half-life was approximately 12–16 h. After intravenous administration, 50% of the drug was excreted as prototypes, most of them were excreted within 24 h (90% of urine excretion). 6 Amisulpride was mainly metabolized into two inactive metabolites, accounting for 4% of the excreta. Amisulpride is almost entirely renally eliminated -Abstract Truncated-